  Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) came to market in the year 2005 , as a new therapeutic classification , for clinical use in the management of type 2 diabetes mellitus ( T2DM). Since 2005 , there have been six approved products on the market , with the newest product being semaglutide ( Novo Nordisk). Several studies have been conducted and completed evaluating its pharmacokinetics as a once-weekly subcutaneous injection. As a dose of 0.5 or 1 mg , semaglutide has a half-life of 7 days; therefore , it would reach steady state in 4-5 weeks. There are few drug interactions and dose adjustments are not necessary. However , similar to other GLP-1 RAs , semaglutide can delay gastric emptying and may impact the absorption of oral medications. Based on clinical trials , semaglutide has been compared with placebo , sitagliptin , exenatide extended release , and insulin glargine as monotherapy or add-on therapy. Semaglutide has resulted in a 1.5-1.9 % glycosylated hemoglobin A